MY170729A - 4-(8-methoxy -i- (( 1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor - Google Patents

4-(8-methoxy -i- (( 1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Info

Publication number
MY170729A
MY170729A MYPI2014700328A MYPI2014700328A MY170729A MY 170729 A MY170729 A MY 170729A MY PI2014700328 A MYPI2014700328 A MY PI2014700328A MY PI2014700328 A MYPI2014700328 A MY PI2014700328A MY 170729 A MY170729 A MY 170729A
Authority
MY
Malaysia
Prior art keywords
dimethylisoxazole
methoxypropan
quinolin
imidazo
pyran
Prior art date
Application number
MYPI2014700328A
Other languages
English (en)
Inventor
Emmanuel Hubert Demont
Katherine Louise Jones
Robert J Watson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MY170729A publication Critical patent/MY170729A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2014700328A 2011-08-17 2012-08-15 4-(8-methoxy -i- (( 1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor MY170729A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1114103.3A GB201114103D0 (en) 2011-08-17 2011-08-17 Novel compounds

Publications (1)

Publication Number Publication Date
MY170729A true MY170729A (en) 2019-08-27

Family

ID=44764570

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014700328A MY170729A (en) 2011-08-17 2012-08-15 4-(8-methoxy -i- (( 1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Country Status (38)

Country Link
US (4) US9067936B2 (en:Method)
EP (2) EP2744809B1 (en:Method)
JP (1) JP6059723B2 (en:Method)
KR (1) KR20140064878A (en:Method)
CN (1) CN103889984B (en:Method)
AR (1) AR087545A1 (en:Method)
AU (1) AU2012296914B2 (en:Method)
BR (1) BR112014003681A8 (en:Method)
CA (1) CA2843537A1 (en:Method)
CL (1) CL2014000365A1 (en:Method)
CO (1) CO6862151A2 (en:Method)
CR (1) CR20140076A (en:Method)
CY (1) CY1118370T1 (en:Method)
DK (1) DK2744809T3 (en:Method)
DO (1) DOP2014000031A (en:Method)
EA (1) EA023374B1 (en:Method)
ES (1) ES2609857T3 (en:Method)
GB (1) GB201114103D0 (en:Method)
HR (1) HRP20161674T1 (en:Method)
HU (1) HUE030106T2 (en:Method)
IL (1) IL230489A (en:Method)
IN (1) IN2014CN00568A (en:Method)
JO (1) JO3187B1 (en:Method)
LT (1) LT2744809T (en:Method)
ME (1) ME02589B (en:Method)
MX (1) MX350597B (en:Method)
MY (1) MY170729A (en:Method)
PE (1) PE20141406A1 (en:Method)
PH (1) PH12014500379A1 (en:Method)
PL (1) PL2744809T3 (en:Method)
PT (1) PT2744809T (en:Method)
RS (1) RS55560B1 (en:Method)
SI (1) SI2744809T1 (en:Method)
SM (2) SMT201700005T1 (en:Method)
TW (1) TWI558704B (en:Method)
UA (1) UA110838C2 (en:Method)
UY (1) UY34264A (en:Method)
WO (1) WO2013024104A1 (en:Method)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
CN105377851B (zh) 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
MX2015012005A (es) * 2013-03-11 2016-04-04 Abbvie Inc Inhibidores de bromodominio.
WO2014164780A1 (en) 2013-03-11 2014-10-09 Abbvie Inc. Fused tetracyclic bromodomain inhibitors
EA038494B1 (ru) 2013-03-15 2021-09-07 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
SG10201710705UA (en) 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
KR20160038008A (ko) 2013-07-31 2016-04-06 제니쓰 에피제네틱스 코포레이션 브로모도메인 억제제로서 신규 퀴나졸리논
WO2015049629A1 (en) * 2013-10-01 2015-04-09 Piramal Enterprises Limited Imidazoquinoline compounds as bromodomain inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
AU2015222887B2 (en) 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
ME03763B (me) 2014-04-23 2021-04-20 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
US10259809B2 (en) 2015-02-03 2019-04-16 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2016186453A1 (en) * 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2017024408A1 (en) 2015-08-11 2017-02-16 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
WO2017024412A1 (en) 2015-08-12 2017-02-16 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
CN109071562B (zh) 2016-02-15 2022-03-22 密执安大学评议会 作为bet溴结构域抑制剂的稠合1,4-氧氮杂䓬和相关类似物
CN109311900A (zh) 2016-04-06 2019-02-05 密执安大学评议会 用于配体依赖性靶蛋白质降解的单官能中间体
MX2018012174A (es) 2016-04-06 2019-07-08 Univ Michigan Regents Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2).
SG11201808729WA (en) 2016-04-12 2018-11-29 Univ Michigan Regents Bet protein degraders
SG11201811416VA (en) 2016-06-20 2019-01-30 Incyte Corp Crystalline solid forms of a bet inhibitor
CN110072866A (zh) 2016-09-13 2019-07-30 密执安大学评议会 作为bet蛋白降解剂的稠合的1,4-二氮杂*
EP3512855B1 (en) 2016-09-13 2022-07-27 The Regents of the University of Michigan Fused 1,4-oxazepines as bet protein degraders
EP3577120A1 (en) 2017-02-03 2019-12-11 The Regents of The University of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
WO2019055444A1 (en) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
CN108033957A (zh) * 2018-01-09 2018-05-15 中国药科大学 一种喹啉类BET bromodomain抑制剂及其制备方法和用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022132049A1 (en) * 2020-12-17 2022-06-23 National University Of Singapore Treating cancers using bet inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1590348A1 (en) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
DK1699512T3 (da) 2003-11-03 2012-09-17 Glaxo Group Ltd Fluiddispenseringsindretning
WO2005054237A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
US20090240055A1 (en) 2005-09-23 2009-09-24 Krepski Larry R Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof
CN101330916A (zh) 2005-12-16 2008-12-24 科勒制药集团公司 经取代的咪唑并喹啉、咪唑并萘啶和咪唑并吡啶、其组合物及其方法
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
JP5478262B2 (ja) * 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
JP5702396B2 (ja) * 2009-11-05 2015-04-15 グラクソスミスクライン エルエルシー ベンゾジアゼピンブロモドメイン阻害剤
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
US20170157113A1 (en) 2017-06-08
TWI558704B (zh) 2016-11-21
KR20140064878A (ko) 2014-05-28
HRP20161674T1 (hr) 2017-01-27
GB201114103D0 (en) 2011-09-28
HUE030106T2 (en) 2017-04-28
BR112014003681A8 (pt) 2018-01-23
MX2014001834A (es) 2014-02-27
US20150315184A1 (en) 2015-11-05
US9861627B2 (en) 2018-01-09
MX350597B (es) 2017-09-11
EP3150601A1 (en) 2017-04-05
CL2014000365A1 (es) 2014-07-11
US9416130B2 (en) 2016-08-16
UA110838C2 (uk) 2016-02-25
EA201490200A1 (ru) 2014-07-30
PL2744809T3 (pl) 2017-08-31
JP6059723B2 (ja) 2017-01-11
AR087545A1 (es) 2014-04-03
IL230489A0 (en) 2014-03-31
BR112014003681A2 (pt) 2017-03-01
US9610284B2 (en) 2017-04-04
CR20140076A (es) 2014-03-19
CA2843537A1 (en) 2013-02-21
EP2744809B1 (en) 2016-10-12
SMT201700005T1 (it) 2017-03-08
UY34264A (es) 2013-04-05
NZ620263A (en) 2016-04-29
DOP2014000031A (es) 2014-06-01
PE20141406A1 (es) 2014-10-25
AU2012296914B2 (en) 2016-03-03
JP2014521735A (ja) 2014-08-28
SMT201700005B (it) 2017-03-08
WO2013024104A1 (en) 2013-02-21
JO3187B1 (ar) 2018-03-08
US20140171462A1 (en) 2014-06-19
EA023374B1 (ru) 2016-05-31
CO6862151A2 (es) 2014-02-10
ES2609857T3 (es) 2017-04-24
IL230489A (en) 2016-07-31
AU2012296914A1 (en) 2014-02-13
PT2744809T (pt) 2017-01-06
CY1118370T1 (el) 2017-06-28
SI2744809T1 (sl) 2017-01-31
CN103889984B (zh) 2016-01-13
DK2744809T3 (en) 2017-01-23
US20160317529A1 (en) 2016-11-03
LT2744809T (lt) 2016-12-27
CN103889984A (zh) 2014-06-25
EP2744809A1 (en) 2014-06-25
IN2014CN00568A (en:Method) 2015-04-03
TW201323424A (zh) 2013-06-16
US9067936B2 (en) 2015-06-30
PH12014500379A1 (en) 2021-07-12
ME02589B (me) 2017-06-20
RS55560B1 (sr) 2017-05-31

Similar Documents

Publication Publication Date Title
MY170729A (en) 4-(8-methoxy -i- (( 1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CA2818187C (en) Bromodomain inhibitors and uses thereof
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
BR112012023382A2 (pt) compostos, composições e métodos de uso de imidazopiridina.
MX2015017964A (es) Inhibidores de bromodominio.
NZ706739A (en) Substituted benzene compounds
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
NZ708870A (en) Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
IN2014DN10386A (en:Method)
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
IN2015DN02109A (en:Method)
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
HK1193411A (en) 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors